CN112203631B - Deodorant and passivating agent - Google Patents
Deodorant and passivating agent Download PDFInfo
- Publication number
- CN112203631B CN112203631B CN201980035247.8A CN201980035247A CN112203631B CN 112203631 B CN112203631 B CN 112203631B CN 201980035247 A CN201980035247 A CN 201980035247A CN 112203631 B CN112203631 B CN 112203631B
- Authority
- CN
- China
- Prior art keywords
- component
- stress
- extract
- deodorizing
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 52
- 239000002781 deodorant agent Substances 0.000 title abstract description 78
- 230000001877 deodorizing effect Effects 0.000 claims abstract description 78
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 72
- 239000011787 zinc oxide Substances 0.000 claims abstract description 36
- 229910021536 Zeolite Inorganic materials 0.000 claims abstract description 28
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims abstract description 28
- 230000003340 mental effect Effects 0.000 claims abstract description 28
- 239000010457 zeolite Substances 0.000 claims abstract description 28
- 229910052709 silver Inorganic materials 0.000 claims abstract description 27
- 239000004332 silver Substances 0.000 claims abstract description 27
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000004615 ingredient Substances 0.000 claims abstract description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 18
- 229960001295 tocopherol Drugs 0.000 claims abstract description 18
- 229930003799 tocopherol Natural products 0.000 claims abstract description 18
- 239000011732 tocopherol Substances 0.000 claims abstract description 18
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 18
- 229940094522 laponite Drugs 0.000 claims abstract description 15
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 claims abstract description 15
- 235000004347 Perilla Nutrition 0.000 claims abstract description 13
- 240000002943 Elettaria cardamomum Species 0.000 claims abstract description 12
- 235000005300 cardamomo Nutrition 0.000 claims abstract description 12
- 244000237986 Melia azadirachta Species 0.000 claims abstract description 8
- 235000013500 Melia azadirachta Nutrition 0.000 claims abstract description 8
- 244000124853 Perilla frutescens Species 0.000 claims abstract 5
- YWHLKYXPLRWGSE-UHFFFAOYSA-N Dimethyl trisulfide Chemical compound CSSSC YWHLKYXPLRWGSE-UHFFFAOYSA-N 0.000 claims description 50
- ULIKDJVNUXNQHS-UHFFFAOYSA-N 2-Propene-1-thiol Chemical compound SCC=C ULIKDJVNUXNQHS-UHFFFAOYSA-N 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 22
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 claims description 15
- KLTVSWGXIAYTHO-UHFFFAOYSA-N 1-Octen-3-one Chemical compound CCCCCC(=O)C=C KLTVSWGXIAYTHO-UHFFFAOYSA-N 0.000 claims description 14
- 230000000415 inactivating effect Effects 0.000 claims description 14
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims description 10
- 102400001107 Secretory component Human genes 0.000 claims description 10
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 claims description 10
- 235000009008 Eriobotrya japonica Nutrition 0.000 claims description 9
- 229940094952 green tea extract Drugs 0.000 claims description 9
- 235000020688 green tea extract Nutrition 0.000 claims description 9
- 229940057070 sugarcane extract Drugs 0.000 claims description 9
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 8
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000002161 passivation Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 231100000676 disease causative agent Toxicity 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 4
- 244000061508 Eriobotrya japonica Species 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract description 9
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract description 9
- 229940002508 ginger extract Drugs 0.000 abstract 2
- 235000020708 ginger extract Nutrition 0.000 abstract 2
- 230000035882 stress Effects 0.000 description 107
- 230000000694 effects Effects 0.000 description 25
- 230000008451 emotion Effects 0.000 description 14
- 230000035943 smell Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 150000003464 sulfur compounds Chemical class 0.000 description 9
- 241000229722 Perilla <angiosperm> Species 0.000 description 8
- 208000035985 Body Odor Diseases 0.000 description 7
- 241001092070 Eriobotrya Species 0.000 description 7
- 206010040904 Skin odour abnormal Diseases 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 230000036651 mood Effects 0.000 description 6
- 230000001107 psychogenic effect Effects 0.000 description 6
- -1 silver ions Chemical group 0.000 description 6
- 238000004332 deodorization Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 230000004800 psychological effect Effects 0.000 description 4
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- OTKQNSSMCDLVQV-UHFFFAOYSA-N Butyl 2-methylbutanoate Chemical compound CCCCOC(=O)C(C)CC OTKQNSSMCDLVQV-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010020400 Hostility Diseases 0.000 description 2
- ZOYASYRPGHCQHW-UHFFFAOYSA-N Methyl propyl trisulfide Chemical compound CCCSSSC ZOYASYRPGHCQHW-UHFFFAOYSA-N 0.000 description 2
- 102000012547 Olfactory receptors Human genes 0.000 description 2
- 108050002069 Olfactory receptors Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- VVGOCOMZRGWHPI-ARJAWSKDSA-N (z)-4-heptenal Chemical compound CC\C=C/CCC=O VVGOCOMZRGWHPI-ARJAWSKDSA-N 0.000 description 1
- VFRRCEIJQYJSAY-UHFFFAOYSA-N 2,2,3-trimethylhexanal Chemical compound CCCC(C)C(C)(C)C=O VFRRCEIJQYJSAY-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 240000003237 Hedychium spicatum Species 0.000 description 1
- 235000015030 Hedychium spicatum Nutrition 0.000 description 1
- CCEFMUBVSUDRLG-XNWIYYODSA-N Limonene-1,2-epoxide Chemical compound C1[C@H](C(=C)C)CCC2(C)OC21 CCEFMUBVSUDRLG-XNWIYYODSA-N 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001343 butyl (2R)-2-methylbutanoate Substances 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000010806 kitchen waste Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229930006978 terpinene Natural products 0.000 description 1
- 150000003507 terpinene derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/01—Deodorant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Disinfection, Sterilisation Or Deodorisation Of Air (AREA)
Abstract
The present invention provides a deodorant for deodorizing stress odor and a passivating agent for passivating psychological or mental activities due to stress odor components. The deodorant and the passivating agent contain at least one of the 1 st deodorizing component and the 2 nd deodorizing component. The 1 st deodorizing ingredient contains at least one selected from the group 1 consisting of silver-loaded zeolite, tocopherol, zinc oxide, casomona ginger extract, red-ball ginger extract, and combinations thereof. The 2 nd deodorizing component comprises a deodorizing ingredient selected from laponite, silver-loaded zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, and hydroxypropyl-β-at least one of group 2 consisting of cyclodextrin, tsaoko cardamon extract, tocopherol, and combinations thereof.
Description
RELATED APPLICATIONS
The present invention is based on the japanese patent application: priority claims of japanese patent application No. 2018-100599 (application No. 2018, 5, 25), the entire contents of which are incorporated by reference and described in the present specification.
Technical Field
The present disclosure relates to deodorant agents that eliminate or reduce unpleasant sensations caused by body odor. The present disclosure relates to passivating agents that passivate the physiological/psychological activity (bias) effects of secreted components derived from the human body.
Background
The odor caused by the odor components emitted from the skin of the human body is often an unpleasant odor, and is generally called "body odor". For example, "aged person's odor (aging odor)" is known as a body odor specific to middle-aged and elderly persons (for example, refer to patent document 1). In order to eliminate unpleasant feeling caused by the odor of the elderly, the flavor composition for inhibiting the odor of the elderly described in patent document 1 is blended with a component having an excellent masking effect on the odor of the elderly and/or a component having an excellent blending effect on the odor of the elderly.
In addition, sulfur compounds are generally considered to be unpleasant odor components. Patent document 2 discloses an odor inhibitor of a polysulfide compound selected from the group consisting of butyl 2-methylbutyrate,α-at least one of terpinene, dipentene, cis-4-heptenal, 1, 4-eucalyptol, trimethylhexanal and (+) -limonene oxide as an active ingredient.
Prior art literature
Patent literature
Patent document 1: japanese patent laid-open No. 11-286428;
patent document 2: WO2016/204212A1.
Disclosure of Invention
Problems to be solved by the invention
The inventors noted that: there is a characteristic odor around a person in a stress state (stress state) in which the heart rate increases due to mental stress. Therefore, the present inventors have found that, when studying the cause of this odor: the malodor is body odor (hereinafter, referred to as "stress odor" or "stress odor" in the present disclosure) caused by substances secreted/released by a person in a stress state or a mental stress state.
The stress odor is a sulfur-based odor, and is an unpleasant odor for many people. In recent years, attention to body odor has also been raised, and there has been a predicted need for a deodorant capable of eliminating or alleviating unpleasant feeling caused by stress odor.
The odor inhibitor described in patent document 2 only mentions malodors originating from outside the human body such as a water outlet and kitchen waste, and the malodors emitted from the human body are not discussed, and it is not clear whether the odor inhibitor described in patent document 2 can suppress stress malodor.
The inventors consider that: at least one of a physiologically active effect and a psychoactive effect exists in a component secreted and released from a person in a stress state or a mental stress state (for example, a causative substance of stress odor). Therefore, there is expected to be an increase in the demand for a passivating agent that passivates the physiologically active effect and/or psychoactive effect of a component secreted from a person in a stress state and/or a mental stress state (hereinafter, referred to as "stress component").
Means for solving the problems
According to the 1 st aspect of the present disclosure, there is provided a stress deodorizing agent comprising at least one of the 1 st deodorizing component and the 2 nd deodorizing component. The 1 st deodorizing ingredient contains at least one selected from the 1 st group consisting of silver-loaded zeolite, tocopherol, zinc oxide, and combinations thereof. The 2 nd deodorizing ingredient comprises a deodorizing ingredient selected from Laponite (Laponite), silver-loaded zeolite, zinc oxide, neem leaf (Neem leaf) extract, iris root (Iris root) extract, perilla leaf extract, and hydroxypropyl-β-at least one of group 2 consisting of cyclodextrin, tsaoko drug (Hedychium spicatum) extract, tocopherol, and combinations thereof.
According to the 2 nd aspect of the present disclosure, there is provided a stress deodorizing agent comprising at least one of the 1 st deodorizing component and the 2 nd deodorizing component. 1 st deodorant component comprisesAt least one of group 1 consisting of a silver-loaded zeolite, tocopherol, zinc oxide, and combinations thereof. The 2 nd deodorizing ingredient contains: zinc oxide; selected from laponite, silver-loaded zeolite, dibutyl hydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, and hydroxypropyl-β-at least one of group 3 consisting of cyclodextrin, tsaoko cardamon extract, green tea extract, and combinations thereof.
According to the 3 rd aspect of the present disclosure, there is provided a passivating agent comprising at least one of a1 st deodorizing component and a 2 nd deodorizing component. The 1 st deodorizing ingredient contains at least one selected from the 1 st group consisting of silver-loaded zeolite, tocopherol, zinc oxide, and combinations thereof. The 2 nd deodorizing component comprises a deodorizing ingredient selected from laponite, silver-loaded zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, and hydroxypropyl-β-at least one of group 2 consisting of cyclodextrin, tsaoko cardamon extract, tocopherol, and combinations thereof. The inactivating agent inactivates the psychogenic or psychogenic active effects of the secreted component.
According to the 4 th aspect of the present disclosure, there is provided a passivating agent comprising at least one of a1 st deodorizing component and a 2 nd deodorizing component. The 1 st deodorizing ingredient contains at least one selected from the 1 st group consisting of silver-loaded zeolite, tocopherol, zinc oxide, and combinations thereof. The 2 nd deodorizing ingredient contains: zinc oxide; selected from laponite, silver-loaded zeolite, dibutyl hydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, and hydroxypropyl-β-at least one of group 3 consisting of cyclodextrin, tsaoko cardamon extract, green tea extract, and combinations thereof. The inactivating agent inactivates the psychogenic or psychogenic active effects of the secreted component.
Effects of the invention
According to the deodorant of the present disclosure, the unpleasant feeling based on tension odor can be eliminated or reduced.
According to the passivating agent disclosed by the disclosure, the psychological or physiological activity effect caused by the stress odor component can be passivated or inhibited.
Drawings
FIG. 1 is a graph showing the results in example 4.
Detailed Description
Hereinafter, preferred embodiments from the above viewpoints are described.
According to the preferred mode of the above-mentioned aspects 1 and 2, the stress odor is an odor that is emitted from the body due to a stress state and/or mental stress.
According to a preferred mode of the above-mentioned viewpoints 1 and 2, the substance responsible for stress contains at least one of allyl mercaptan and dimethyl trisulfide.
According to a preferred embodiment of the above-described aspects 1 and 2, the causative substance further contains at least one compound selected from the group consisting of methyl mercaptan, dimethyl sulfide, dimethyl disulfide, and a combination thereof.
According to a preferred mode of the above-mentioned aspects 1 and 2, the causative agent further comprises 1-octen-3-one.
According to the preferred mode of the above-mentioned aspects 3 and 4, the secretory component is a component secreted in vivo due to stress and/or mental stress.
According to a preferred mode of the above-mentioned viewpoints 3 and 4, the secretory component contains at least one of allyl mercaptan and dimethyl trisulfide.
According to a preferred mode of the above-mentioned aspects 3 and 4, the secretory component further contains at least one compound selected from the group consisting of methyl mercaptan, dimethyl sulfide, dimethyl disulfide, and a combination thereof.
According to a preferred mode of the above-mentioned aspects 3 and 4, the secretory component further comprises 1-octen-3-one.
The deodorant according to embodiment 1 of the present disclosure will be described.
The deodorant of the present disclosure is a deodorant that can be suitably applied to body odor (stress odor) emitted when a person is in a stress state and/or a mental stress state. The deodorant in the present disclosure refers to a substance that removes or alleviates malodor by chemical action and/or physical action against causative substances of malodor to be deodorized (hereinafter, referred to as "malodor"). Even if the components listed in the present disclosure remove or mitigate malodor by means other than chemical and/or physical effects, the deodorant of the present disclosure is not beyond the scope of the present disclosure.
The deodorant of the present disclosure contains at least one of the 1 st deodorant component and the 2 nd deodorant component.
The 1 st deodorizing ingredient may contain at least one selected from the 1 st group consisting of silver-loaded zeolite, tocopherol, zinc oxide (powder), and combinations thereof. The 1 st deodorizing ingredient is considered to be useful for deodorizing malodor caused by stress odor, particularly allyl mercaptan.
In the present disclosure, the silver-loaded zeolite includes, for example, a zeolite in which at least a part of ions capable of ion exchange in the zeolite is substituted with silver ions. The silver ion content in the silver-loaded zeolite may be, for example, 0.1 to 15 mass%.
The 2 nd deodorizing component may comprise a component selected from laponite, silver-loaded zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, and hydroxypropyl-β-at least one of group 2 consisting of cyclodextrin, tsaoko cardamon extract, tocopherol, dibutyl hydroxy toluene, sugarcane extract, loquat leaf extract, green tea extract, and combinations thereof. The 2 nd deodorizing ingredient is considered to be useful for deodorizing malodor caused by stress odor, particularly dimethyl trisulfide.
The 2 nd deodorizing ingredient preferably contains (a) zinc oxide; and (B) is selected from laponite, silver-loaded zeolite, dibutyl hydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-containing materialβ-at least one of group 3 consisting of cyclodextrin, tsaoko cardamon extract, green tea extract, and combinations thereof. By using this combination, the deodorizing effect of the stress smell can be further improved.
The zinc oxide may be finely powdered. The average particle diameter of zinc oxide can be set to 5μm is less than or equal to 3μm is less than or equal to 2μm is less than or equal to 1μm is less than or equal to 0.5μm is less than or equal to m.
As described later, the main components of the causative substances of stress are allyl mercaptan and dimethyl trisulfide. The influence of these two substances on the smell is particularly great. Thus, if the malodors of allyl mercaptan and dimethyl trisulfide are deodorized, the stress odor can be effectively deodorized.
The method of using the deodorant of the present disclosure and the method of deodorizing tension odor will be described.
The deodorant of the present disclosure may be dispersed in the air in places where a tension smell is generated and/or places where a tension smell is likely to be generated, in advance and/or after. The deodorant may also be attached to or dispersed throughout clothing, curtains, carpets, and the like, prior to and/or after the application. The deodorant may be applied to the skin before and/or after the skin without adversely affecting the skin. For example, the deodorant may be applied to a site where it is thought to secrete a stress-smelling component, such as the palm, armpits, feet, back, head, face, mouth, etc.
The deodorant of the present disclosure may be used in combination with other deodorants, substances that remove or mitigate malodor by chemical/biological/physical action, or the like. For example, the deodorant of the present disclosure may further contain a deodorizing component, another deodorizing component, and the like, within a range that does not hinder the effect of the deodorant of the present disclosure.
According to the deodorant of the present disclosure, the unpleasant sensation generated when smelling a tension odor can be eliminated or suppressed. In addition, by using the deodorant of the present disclosure, a person who is in a stress state or a mental stress state or a person who is in a stress state or a mental stress state in the future may be relieved or relaxed in advance and/or after, and a feeling of anxiety which may be generating a stress odor may be generated.
A passivating agent according to embodiment 2 of the present disclosure will be described.
The stress odor component has at least one of psychological and physiological activities for human. For example, in the case where a person perceives a stress odor, in the case where an olfactory receptor responds to a stress odor component, and the like, the person becomes more and more mentally tired, disordered, awake. The stress component may also have a psychoactive effect and/or a psychoactive effect other than these. The passivating agent of the present disclosure has an effect of passivating the psychoactive effect and/or psychoactive effect of the stress component. That is, where a person perceives the scent of the passivating agent of the present disclosure, where the scent of the passivating agent and the stress odor mix and are smelled, where the olfactory receptor responds to the passivating agent, and the like, the person may eliminate or suppress the mental bias and/or psychological bias as described above.
In particular, it has been clarified that: if a person perceives a tension smell, the negative emotion will increase. In addition, there is clearly a trend of decreasing the positive emotion. As negative emotions, for example, there may be mentioned: "anger/hostility", "confusion/confusion", "depression/collapse", "fatigue/burnout" and "tension/restlessness" checked in accordance with POMS (registered trademark) (mood state table, profile of Mood States). It is known that stress smell can increase, among others, "confusion/confusion", "fatigue/burnout" and "stress/restlessness". In addition, examples of positive emotions include "liveness/vitality" and "friendly".
The passivating agent of the present disclosure comprises at least one of a1 st passivating component and a 2 nd passivating component.
The 1 st passivation component may comprise at least one selected from group 1 consisting of silver-loaded zeolite, tocopherol, zinc oxide, and combinations thereof. The 1 st inactivating component is considered to be useful for the inactivation of malodors caused by stress, particularly allyl mercaptan.
The passivation component 2 may comprise a material selected from laponite, silver-loaded zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, and hydroxypropyl-β-at least one of group 2 consisting of cyclodextrin, tsaoko cardamon extract, tocopherol, dibutyl hydroxy toluene, sugarcane extract, loquat leaf extract, green tea extract, and combinations thereof. The 2 nd inactivating component is considered to be useful for the inactivation of malodor caused by a substance responsible for stress odor, particularly dimethyl trisulfide.
The 2 nd passivation component preferably comprises (A) zinc oxideThe method comprises the steps of carrying out a first treatment on the surface of the And (B) is selected from laponite, silver-loaded zeolite, dibutyl hydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-containing materialβ-at least one of group 3 consisting of cyclodextrin, tsaoko cardamon extract, green tea extract, and combinations thereof. By using this combination, the effect of inactivating the stress odor can be further improved.
The zinc oxide may be finely powdered. The average particle diameter of zinc oxide can be set to 5μm is less than or equal to 3μm is less than or equal to 2μm is less than or equal to 1μm is less than or equal to 0.5μm is less than or equal to m.
The psychological and physiological activities of the stress component and the inactivation of the stress component by the inactivating agent can be examined by using a psychological questionnaire method, such as POMS (registered trademark) (mood state scale, profile of Mood States), GACL (General Activity Checklist), and the like.
As described later, the main components of the causative substances of stress are allyl mercaptan and dimethyl trisulfide. The influence of these two substances on the smell is particularly great. Thus, if the malodors of allyl mercaptan and dimethyl trisulfide are deodorized, the psychogenic and/or physiologically active effects due to stress can be effectively inactivated.
The method of using the passivating agent of the present disclosure and the method of passivating the stress-odor component will be described.
The passivating agents of the present disclosure may be dispersed in the air at the site where the malodorous component is generated and/or at the site where the malodorous component is likely to be generated, in advance and/or after the fact. The passivating agent may also be attached to or dispersed on clothing, curtains, carpets, etc. in advance and/or after the application. In the case where the passivating agent does not adversely affect the skin, the passivating agent may be applied to the skin in advance and/or after the skin. For example, the passivating agent may be applied to a site that is believed to secrete a stress odor component, such as the palm, armpits, feet, back, head, face, mouth, etc.
The passivating agents of the present disclosure may be used in combination with other psychogenic/physiological effect passivating agents and the like. For example, the passivating agent of the present disclosure may further contain other passivating agents within a range that does not hinder the effect of the passivating agent of the present disclosure. Examples of the other passivating agents include: malodor (e.g., stress malodor) is removed or alleviated by chemical/biological/physical action or the like.
The passivating agents of the present disclosure may inactivate the psychoactive and/or psychoactive effects of the stress component. Thus, psychological bias, physiological bias, etc. caused by the stress and odor components can be eliminated or suppressed. By using the passivating agent of the present disclosure, a person in a stress state or mental stress state or a person who is in a stress state or mental stress state in the future may take countermeasures against psychological bias, physiological bias, or the like in advance and/or after.
The method for producing the deodorant and the passivating agent of the present disclosure is not particularly limited. For example, the deodorant and the passivating agent may be prepared by mixing deodorant components.
The stress odor and the stress odor component described in the present disclosure are explained.
Stress odor refers to an odor that is emitted from the body when under stress or when subjected to mental stress. The stress or mental stress mentioned here may be exemplified by: stress or pressure based on personal relationships, etc. Based on stress/pressure with the person, for example, there may be listed: tension/stress during publication in front of others, especially in front of the crowd, tension/stress during acceptance of important interviews or stressful interviews, etc. Such mental stress states may also be, for example: in the absence of an increase in heart rate due to exercise, the heart rate per 1 minute will be 20bpm or more (heartbeat per minute) higher, preferably 30bpm or more, than that at rest. The calm state refers to a state where there is no mental stress and there is little heart rate fluctuation, for example, a state where the user sits down and relaxes for a predetermined time or longer.
Stress odor is considered to be based on the components contained in blood. In the present disclosure, "self-produced (secretion/release)" means produced (secretion/release) from the skin, mucous membrane and/or oral cavity. The term "body odor" as used in this disclosure also includes bad breath.
The stress component contains a compound containing a sulfur element (sulfur compound). The sulfur compound includes at least one of allyl mercaptan and dimethyl trisulfide. Preferably, the stress component comprises both allyl mercaptan and dimethyl trisulfide.
The allyl mercaptan may be 0.1ppb or more, 0.3ppb or more, 0.5ppb or more, 1ppb or more, or 10ppb or more, on a volume basis. The allyl mercaptan may be 1,000ppm or less, 100ppm or less, 10ppm or less, 1ppm or less, 500ppb or less, 100ppb or less, or 10ppb or less, on a volume basis.
The dimethyl trisulfide may be 1ppb or more, 2ppb or more, 3ppb or more, 5ppb or more, 10ppb or more, 20ppb or more, 50ppb or more, or 100ppb or more in terms of volume standard. The dimethyl trisulfide may be 10,000ppm or less, 1,000ppm or less, 100ppm or less, 10ppm or less, 1ppm or less, 100ppb or less, or 10ppb or less, on a volume basis.
In the stress component, regarding the mass ratio of allyl mercaptan to dimethyl trisulfide, for example, the dimethyl trisulfide may be 2 parts by mass or more, 5 parts by mass or more, 10 parts by mass or more, or 15 parts by mass or more with respect to 1 part by mass of allyl mercaptan. Regarding the mass ratio of allyl mercaptan to dimethyl trisulfide, for example, the dimethyl trisulfide may be 50 parts by mass or less, 40 parts by mass or less, 30 parts by mass or less, or 25 parts by mass or less with respect to 1 part by mass of allyl mercaptan.
The stress component may further contain at least one compound selected from the group consisting of hydrogen sulfide, methyl mercaptan, carbon disulfide, dimethyl sulfide, dimethyl disulfide, methyl propyl trisulfide, and combinations thereof as a sulfur compound other than allyl mercaptan and dimethyl trisulfide (hereinafter, referred to as "other sulfur compound"). The total amount of sulfur compounds may be 0.1ppb or more, 1ppb or more, or 10ppb or more in terms of volume. The total amount of sulfur compounds may be 10,000ppm or less or 1,000ppm or less by volume.
The stress component may contain 1-octen-3-one as a non-sulfur compound in addition to or separately from the sulfur compound. The 1-octen-3-one may be, for example, 0.1ppb or more, 0.5ppb or more, 1ppb or more, 10ppb or more, 100ppb or more, or 1ppm or more in terms of volume. The 1-octen-3-one may be, for example, 1,000ppm or less, 100ppm or less, 10ppm or less, or 1ppm or less, based on the volume.
Examples
Hereinafter, the deodorant and the passivating agent of the present disclosure will be described by way of examples. However, the deodorant and the passivating agent of the present disclosure are not limited to the following examples.
Example 1: deodorization test against dimethyl trisulfide ]
0.05 mass% of deodorant and 99.95 mass% of dipropylene glycol were mixed to prepare deodorant solutions of the respective deodorants. 1mL of the deodorant solution and 5X 10 parts by mass of the deodorant per 1 part by mass of the deodorant -4 The dimethyl trisulfide was injected into a 30 mL-volume sample tube. The odor in the sample tube was smelled by 3 panelists, and the deodorizing effect of each deodorizing agent against dimethyl trisulfide was evaluated according to the following criteria.
[ deodorizing Effect of substances against stress odor ]
2, the method comprises the following steps: the professional panel evaluates that the deodorant has high deodorant effect;
1, the method comprises the following steps: the professional panel evaluates that the deodorizing effect of the deodorizing agent is slightly higher;
0 point: the expert panelists rated the deodorant as having no deodorizing effect.
The evaluation of the deodorizing effect of each deodorizing agent by the tested deodorizing agent and the expert panelist is shown in table 1. The evaluations shown in table 1 are average scores of professional panelists were recorded according to the following criteria. The average particle size of the zinc oxide used in the examples below was about 0.2μm。
A:2, dividing;
b: more than 1.5 minutes and less than 2 minutes;
c: more than 1 minute and less than 1.5 minutes;
d: less than 1 minute.
In the deodorant of test examples 1 to 3, the deodorizing effect against dimethyl trisulfide, which is a causative substance of stress odor, was confirmed. Therefore, the deodorant of test examples 1 to 3 is considered to be effective for deodorizing stress odor.
TABLE 1
Example 2: deodorization test against allyl mercaptan
0.10 mass% of deodorant and 99.90 mass% of dipropylene glycol were mixed to prepare deodorant solutions of the respective deodorants. 1mL of the deodorant solution and 5X 10 parts by mass of the deodorant per 1 part by mass of the deodorant -6 The allyl mercaptan was injected into a 30mL volume sample tube in parts by mass. The odor in the sample tube was smelled by 3 panelists, and the deodorizing effect of each deodorizing agent against allyl mercaptan was evaluated according to the following criteria. The evaluation of the deodorizing effect of each deodorizing agent by the tested deodorizing agent and the expert panelist is shown in table 2. The evaluation criteria were the same as in example 1.
In the deodorants of test examples 8 to 16, the deodorizing effect against allyl mercaptan, which is a causative substance of stress odor, was confirmed. Therefore, the deodorant of test examples 8 to 16 is considered to be effective for deodorizing the stress odor.
TABLE 2
Example 3: deodorization test against allyl mercaptan
0.10 mass% of deodorant and 99.90 mass% of dipropylene glycol were mixed to prepare deodorant solutions of the respective deodorants. The deodorant contains 50% by mass of zinc oxide as component a and 50% by mass of component B shown in table 3. 1mL of the deodorant solution and 2.5X10 parts by mass of the deodorant per 1 part by mass of the deodorant -6 The allyl mercaptan was injected into a 30mL volume sample tube in parts by mass. The odor in the sample tube was smelled by 3 panelists, and the deodorizing effect of each deodorizing agent against allyl mercaptan was evaluated according to the following criteria. Evaluation of deodorant Effect of test deodorant and professional panelist on deodorant Effect of each deodorantThe values are shown in Table 3. The evaluation criteria were the same as in example 1.
If zinc oxide is mixed with other deodorant, the deodorizing effect can be improved as a whole as compared with the use of the deodorant component alone. For example, in comparing test examples 8, 14, 20, 21 and 23 shown in table 2 with test examples 24, 30, 35, 36 and 38 shown in table 3, respectively, by adding zinc oxide to the deodorant used in example 2, the deodorizing effect can be improved as compared with the deodorant alone. For example, although laponite and hydroxypropyl are used aloneβThe deodorizing effect is low when dextrin, sugarcane extract, loquat leaf extract and green tea extract are mixed, but the deodorizing effect can be improved by mixing with zinc oxide. That is, these deodorizing components are considered to have a synergistic effect of deodorizing with zinc oxide. Thus, it is considered that the mixture of a plurality of deodorizing components is more effective for deodorizing stress odor. In particular, it is considered that the deodorant containing zinc oxide as the 2 nd deodorizing component is more effective for deodorizing tension-type malodor.
In comparing test example 10 with test example 26, the deodorizing effect can be improved by increasing the amount of zinc oxide relative to the malodor-causing substances. Thus, if the amount of the deodorant to be applied is increased with respect to the stress smell, the deodorizing effect can be further improved.
TABLE 3
Example 4: deodorization test against stress odor model composition
Preparation of hydroxypropyl-containing Zinc oxide as component A and hydroxypropyl-containing beta as component BβDeodorant shown in table 4 of dextrin. Next, a stress odor model composition containing the stress odor components shown in table 5 was prepared. Next, 100 was mixed in a 100mL sealed glass containerμStress odor model composition of L and 10μL deodorant. Then, the sealed glass container was allowed to stand for 10 minutes, and then the gas component present in the upper space of the sealed glass container was analyzed by a direct mass spectrometry.
As a result, no stress odor component was detected from the upper space of the sealed glass container in which the deodorant and the stress odor model composition were mixed. The stress component is considered to be physically and/or chemically removed from the upper space by adsorption to the deodorant or the like. Thereby confirming that: according to the deodorant of the present invention, stress odor can be effectively deodorized.
TABLE 4
TABLE 5
Example 5: psychology/psychology action test ]
The test subjects were allowed to smell the model composition for stress odor, and psychological/mental changes of the test subjects due to stress odor were confirmed using POMS (registered trademark) and GACL. As a result, it was confirmed that: the subject smells a stress smell, and arouses, fatigues, and confusion.
Second, if the subject is allowed to smell the model composition of stress odor and the deodorant of the present disclosure at the same time, there is no psychological/mental change in the subject as described above. Thus, it was confirmed that: the deodorant of the present disclosure can inactivate psychological/mental effects caused by stress odor (secreted component).
Hereinafter, a test for analyzing a change in mental state by using POMS (registered trademark) 2 adult human short version (Profile of Mood States Second Edition Adult Short) japanese questionnaire will be described in detail. In this psychological analysis, according to the answers of the questionnaire, psychological states concerning "anger/hostility", "confusion/confusion", "depression/collapse", "fatigue/burnout" and "tension/restlessness", which are indexes of negative emotion, and "liveness/vitality" and "friendly", which are indexes of positive emotion, can be confirmed. The questionnaire was provided with 5 questions for each index, and each subject was scored for the emotion to which each question was directed (highest score for each index was 20 points) according to the following criteria.
0 point: nothing is mentioned about emotion;
1, the method comprises the following steps: the emotion mentioned is somewhat;
2, the method comprises the following steps: some of the mentioned emotions;
3, the method comprises the following steps: there are quite a few mentioned emotions;
4, the following steps: there are very many moods mentioned.
First, 8 subjects were left in rest for 20 minutes. The subject is then asked to answer questions of the questionnaire. This check is referred to as "check 1".
Next, each subject was allowed to smell stress continuously for 5 minutes using the lowest concentration of the model composition that each subject can recognize among the stress model compositions shown in table 6. The subject was then asked to answer the same question as in examination 1. This check is referred to as "check 2".
The mean and standard deviation of the scores under each index in checks 1 and 2 were calculated. The results are shown in table 7. A graph of the mean and standard deviation of the scores for each index is shown in fig. 1.
Comparing the results of inspection 1 and inspection 2, it follows that: as shown in fig. 1, negative emotions, in particular stress, confusion and fatigue, are increased by perceived stress odor. On the other hand, a trend of lowering can be confirmed also with respect to the positive emotion. From this, it can be seen that: stress odor has psychological/mental effects that tend to destabilize a person's emotion.
As demonstrated in example 4 above, the deodorant of the present disclosure can remove the stress odor component. Thus, it is appreciated that the deodorant according to the present disclosure may deactivate (eliminate, alleviate, and/or mitigate) the negative psychological/mental effects caused by stress malodor. That is, it is understood that the deodorant of the present disclosure can be applied as a passivating agent against psychological/mental effects of stress odor.
TABLE 6
TABLE 7
The deodorant and the passivating agent of the present disclosure are described with reference to the above embodiments and examples, but are not limited to the above embodiments and examples, and various modifications, alterations and improvements to the respective disclosed elements (including the elements described in the claims, the specification and the drawings) are possible within the scope of the present invention and according to the basic technical ideas of the present invention. In addition, various combinations, substitutions, or selections of the disclosed elements may be made within the scope of the claims of the present invention.
Further objects, purposes and modes of the present invention (including modifications) will be apparent from the entire disclosure of the present invention including the claims.
In the numerical ranges described in the present specification, any numerical value or range included in the range should be interpreted as a numerical value or range specifically described in the present specification even if it is not specifically described.
Claims (9)
1. The use of a combination of the 1 st deodorizing ingredient and the 2 nd deodorizing ingredient for the preparation of a stress deodorizing agent,
the deodorizing component 1 contains at least one selected from the group consisting of silver-loaded zeolite, tocopherol, zinc oxide, and combinations thereof,
the deodorizing ingredient 2 comprises at least one selected from the group consisting of laponite, silver-loaded zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-beta-cyclodextrin, tsaoko cardamon extract, tocopherol, and combinations thereof,
the stress-causing substance contains at least one of allyl mercaptan and dimethyl trisulfide.
2. The use of a combination of the 1 st deodorizing ingredient and the 2 nd deodorizing ingredient for the preparation of a stress deodorizing agent,
the deodorizing component 1 contains at least one selected from the group consisting of silver-loaded zeolite, tocopherol, zinc oxide, and combinations thereof,
the deodorizing component 2 comprises:
zinc oxide; and
at least one selected from group 3 consisting of laponite, silver-loaded zeolite, dibutyl hydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-beta-cyclodextrin, tsaoko cardamon extract, green tea extract, and combinations thereof,
the stress-causing substance contains at least one of allyl mercaptan and dimethyl trisulfide.
3. The use according to claim 1 or 2, wherein said stress odour is an odour emanating from the body as a result of stress and/or mental stress.
4. The use according to claim 1 or 2, wherein the causative agent further comprises at least one compound selected from the group consisting of methyl mercaptan, dimethyl sulfide, dimethyl disulfide, and combinations thereof.
5. The use as claimed in claim 4 wherein said causative agent further comprises 1-octen-3-one.
6. The use of a combination of a1 st inactivating component and a 2 nd inactivating component for the preparation of a inactivating agent for inactivating the psychological or mental activity of a secreted component,
the 1 st passivation component contains at least one selected from the 1 st group consisting of silver-loaded zeolite, tocopherol, zinc oxide, and combinations thereof,
the 2 nd passivation component comprises at least one selected from the group consisting of laponite, silver-loaded zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-beta-cyclodextrin, tsaoko cardamon extract, tocopherol, and combinations thereof,
the secretory component is a component secreted in vivo due to stress and/or mental stress,
the secretory component includes at least one of allyl mercaptan and dimethyl trisulfide.
7. The use of a combination of a1 st inactivating component and a 2 nd inactivating component for the preparation of a inactivating agent for inactivating the psychological or mental activity of a secreted component,
the above-mentioned 1 st passivation component is at least one selected from the group 1 consisting of silver-loaded zeolite, tocopherol, zinc oxide, and combinations thereof,
the 2 nd passivation component comprises:
zinc oxide; and
at least one selected from group 3 consisting of laponite, silver-loaded zeolite, dibutyl hydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-beta-cyclodextrin, tsaoko cardamon extract, green tea extract, and combinations thereof,
the secretory component is a component secreted in vivo due to stress and/or mental stress,
the secretory component includes at least one of allyl mercaptan and dimethyl trisulfide.
8. The use according to claim 6 or 7, wherein said secretory component further comprises at least one compound selected from the group consisting of methyl mercaptan, dimethyl sulfide, dimethyl disulfide, and combinations thereof.
9. The use of claim 8 wherein said secretory component further comprises 1-octen-3-one.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018-100599 | 2018-05-25 | ||
| JP2018100599 | 2018-05-25 | ||
| PCT/JP2019/020760 WO2019225755A1 (en) | 2018-05-25 | 2019-05-24 | Deodorant and deactivating agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112203631A CN112203631A (en) | 2021-01-08 |
| CN112203631B true CN112203631B (en) | 2024-01-30 |
Family
ID=68615566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980035247.8A Active CN112203631B (en) | 2018-05-25 | 2019-05-24 | Deodorant and passivating agent |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP7485597B2 (en) |
| CN (1) | CN112203631B (en) |
| TW (1) | TW202002936A (en) |
| WO (1) | WO2019225755A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0826956A (en) * | 1994-07-19 | 1996-01-30 | Shinagawa Fuel Co Ltd | Deodorant cosmetic |
| CN101528209A (en) * | 2006-10-24 | 2009-09-09 | Sk化学株式会社 | Oleanane triterpene saponin compounds which are effective on treatment of dementia and mild cognitive impairment(MCI), and improvement of cognitive function |
| CN104042469A (en) * | 2014-05-31 | 2014-09-17 | 青岛博泓海洋生物技术有限公司 | Sun cream containing natural plants |
| CN107375047A (en) * | 2017-07-03 | 2017-11-24 | 李剑峰 | Resveratrol cyclodextrin inclusion compound gel and its preparation method and application |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS527060B2 (en) * | 1972-10-23 | 1977-02-26 | ||
| JPS62212316A (en) * | 1986-03-13 | 1987-09-18 | Agency Of Ind Science & Technol | Powdery deodorant |
| JPH09131393A (en) * | 1995-11-10 | 1997-05-20 | Shiseido Co Ltd | Deodorant, deodorizing composition, and deodorizing cosmetic |
| MXPA02001414A (en) * | 1999-08-16 | 2002-07-30 | Pq Holding Inc | Sulfur adsorbent for reducing onion or garlic breath odor. |
| JP4500705B2 (en) * | 2005-02-22 | 2010-07-14 | ニベア花王株式会社 | Deodorant cosmetic |
| JP4721436B2 (en) * | 2006-04-26 | 2011-07-13 | 株式会社 資生堂 | Deodorant composition |
| MY185456A (en) * | 2014-12-12 | 2021-05-19 | Lion Corp | Skin cleanser composition |
| JP2016145197A (en) * | 2015-01-30 | 2016-08-12 | 株式会社コーセー | Deodorant |
| JP6551840B2 (en) * | 2015-09-24 | 2019-07-31 | 株式会社ベネフィット−イオン | Method of manufacturing deodorant products |
-
2019
- 2019-05-24 CN CN201980035247.8A patent/CN112203631B/en active Active
- 2019-05-24 WO PCT/JP2019/020760 patent/WO2019225755A1/en active Application Filing
- 2019-05-24 JP JP2020520404A patent/JP7485597B2/en active Active
- 2019-05-27 TW TW108118250A patent/TW202002936A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0826956A (en) * | 1994-07-19 | 1996-01-30 | Shinagawa Fuel Co Ltd | Deodorant cosmetic |
| CN101528209A (en) * | 2006-10-24 | 2009-09-09 | Sk化学株式会社 | Oleanane triterpene saponin compounds which are effective on treatment of dementia and mild cognitive impairment(MCI), and improvement of cognitive function |
| CN104042469A (en) * | 2014-05-31 | 2014-09-17 | 青岛博泓海洋生物技术有限公司 | Sun cream containing natural plants |
| CN107375047A (en) * | 2017-07-03 | 2017-11-24 | 李剑峰 | Resveratrol cyclodextrin inclusion compound gel and its preparation method and application |
Non-Patent Citations (4)
| Title |
|---|
| NOV (娜芙) 防晒隔离霜SPF35;佚名;《https://www.cosdna.com/chs/cosmetic_8c7c123.html》;20070730;第1-2页 * |
| ORBIS 透妍莹白隔离霜（清爽型）;佚名;《https://www.cosdna.com/chs/cosmetic_5f63140805.html》;20140417;第1-2页 * |
| ORBIS 透妍防晒露（中文标签版）;佚名;《https://www.cosdna.com/chs/cosmetic_934886462.html》;20120814;第1-2页 * |
| 草花木果 防晒霜;佚名;《https://www.cosdna.com/chs/cosmetic_5087266807.html》;20170106;第1-2页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7485597B2 (en) | 2024-05-16 |
| WO2019225755A1 (en) | 2019-11-28 |
| CN112203631A (en) | 2021-01-08 |
| TW202002936A (en) | 2020-01-16 |
| JPWO2019225755A1 (en) | 2021-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019198648A1 (en) | Model composition of body odor, gas composition, gas collection method, and method for determining mental status | |
| WO2002053151A1 (en) | Perfume compositions | |
| JP7082875B2 (en) | Lactone-containing composition for removing malodor | |
| CA2761458C (en) | Fragrance composition having good sleep-inducing effect | |
| KR100763066B1 (en) | Agents and perfume compositions for raising consciousness level | |
| JP2024020230A (en) | Deactivator | |
| CN112203631B (en) | Deodorant and passivating agent | |
| KR100429671B1 (en) | Composite aroma composition for hastenning dophamin neutrotransmitter in the body | |
| JP2007063251A (en) | Method for selecting perfume ingredient and method of perfume formulation | |
| CN107519050A (en) | Tooth gargle is protected in a kind of oral cavity | |
| TWI626058B (en) | Dye / perm agent deodorant preparation and deodorant hair conditioner | |
| JP2005296169A (en) | Deodorant composition | |
| JP2804822B2 (en) | Deodorants | |
| JP6678411B2 (en) | Deodorant and method for deodorizing isovaleric aldehyde | |
| JP2007068625A (en) | Deodorization composition for preserving corpse | |
| JP2003119491A (en) | Perfume composition for psychological exhilaranttion | |
| JP2014111551A (en) | Cosmetic composition | |
| JP2010065233A (en) | Use of specific perfume component for preparing perfume composition for mental stimulation and method of providing mental stimulation effect in perfume composition | |
| JP2008007427A (en) | Hungry feeling alleviation agent | |
| Wineburg | A Study of the Interrelationships Among Olfactory Perception, Affective Suggestion, and the Psychogalvanic Reaction | |
| KR100530385B1 (en) | Fragrance for masking permanent and first permanent and permanent composition comprising the same | |
| JP2023174595A (en) | Method for determining halitosis | |
| JP4648040B2 (en) | Generation method of air for improving biological function | |
| JP2001335501A (en) | Drinking water for deodorant | |
| KR20200127774A (en) | Natural oil composition for refreshing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |